History
Lung cancer has existed for a long time, but until the early 20th century it was recorded as a relatively rare disease. Later, as cigarettes became popular, the number of patients increased sharply, and as evidence accumulated that "smoking is strongly linked to lung cancer," lung cancer became established as a major public health problem. In the early days, even when there were symptoms such as cough and hemoptysis, they were easily mistaken for tuberculosis or chronic bronchitis, and because imaging tests were limited, the disease had often already advanced by the time it was found.
Advances in diagnostic technology greatly changed the course of lung cancer history. As chest X-rays became widespread, large masses could be identified, and later, with the introduction of chest computed tomography (CT), small nodules and lymph node involvement could be seen more accurately. Positron emission tomography (PET) and PET-CT helped evaluate whether metastasis was present by using the metabolic activity of cancer, and bronchoscopy and image-guided biopsy made the process of "confirming with tissue" safer and more precise.
Treatment also expanded from a surgery-centered approach to multidisciplinary treatment. In the early days, the extent of surgery was large and the burden of recovery was heavy, but as minimally invasive surgery such as thoracoscopic surgery developed, recovery and preservation of function improved in some patients. Radiation therapy became more precise, developing in a direction that reduces damage to normal lung, and chemotherapy combinations were systematized according to stage and histologic type.
The key changes of the past ten-plus years are the spread of "molecular diagnosis" and "immunotherapy." In non-small cell lung cancer (NSCLC), when targets such as EGFR and ALK are identified, targeted therapy can be selected, and immune checkpoint inhibitors (ICI) have broadened the possibility of long-term survival in some patients. In addition, with the introduction of low-dose chest CT (LDCT) screening for high-risk groups, the trend toward "finding it before symptoms appear" has been strengthened.
Causes
The biggest cause of lung cancer is tobacco. Tobacco smoke contains many substances that damage DNA, and the longer and more one smokes, the greater the risk. Quitting smoking lowers the risk over time, but the risk does not become "zero," so people with a heavy past smoking history need continued attention. Secondhand smoke also raises the risk and can be a problem especially with long-term indoor exposure.
Causes other than tobacco cannot be ignored either. Among occupational exposures, substances such as asbestos are typical. Asbestos causes chronic inflammation and fibrosis in the lungs and can increase the risk of lung cancer with long-term exposure. Radon gas is produced in the process of decay of naturally occurring radioactive substances and can accumulate indoors in basements or certain building structures. Because radon is colorless and odorless, it is difficult to perceive, and in many cases "you do not know until you measure it," so testing can be helpful in high-concentration areas.
Air pollution is also cited as an important risk factor. Particulate matter such as fine dust produced by vehicle exhaust or fossil fuel combustion can penetrate deep into the lungs and cause inflammation and oxidative stress. There are also reports that indoor smoke generated during cooking or heating (especially in poorly ventilated environments) can increase the risk.
Chronic lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) can share risk factors with lung cancer (smoking) and can also increase the risk on their own through chronic inflammation. Family history and individual constitution also play a role, and because family history can reflect both genetic factors and a shared living environment, individual risk assessment is important.
Genetic Epidemiology
"Genetic epidemiology" is the field that examines how genetic factors and environmental exposures act together in the development of disease. In lung cancer, because a "powerful environmental factor such as smoking" exists, the influence of the environment must also be considered when explaining genetic factors. There are reports that people whose close family members (parents, siblings) have had lung cancer have a higher-than-average risk of lung cancer, and this includes not only genetic factors but also the possibility of having shared similar smoking habits, living environments, and occupational exposures.
Another key point is that genetic changes found in lung cancer do not necessarily mean an "inherited genetic disease." In many cases, lung cells accumulate DNA damage while being exposed to carcinogens throughout life, and in that process genetic changes that exist only in the cancer cells arise. This is a different concept from heredity passed on to family members.
This is clinically important because such genetic changes are directly linked to the choice of treatment. In non-small cell lung cancer (NSCLC), when there are changes such as EGFR, ALK, ROS1, RET, BRAF, MET, or NTRK, drugs aimed at that target can be effective. Recently, interest in "lung cancer in never-smokers" has also grown. In this group, factors other than smoking become relatively more important, and a pattern in which certain molecular alterations are more common has also been observed.
General Epidemiology
Lung cancer is very common worldwide and accounts for a large share of cancer deaths. Incidence varies greatly by country and region, and the biggest reason is the difference in smoking rates. Air pollution, occupational exposure, radon, access to medical care, and screening systems are added to this, making regional patterns differ. Historically it was more common in men, but in some regions the gender gap has narrowed or the pattern has changed due to smoking among women, secondhand smoke, and changes in living environments.
The risk of lung cancer generally increases after age 40, and the age at diagnosis is distributed more among older adults. However, lung cancer can also occur at a young age, and in such cases genetic predisposition, specific molecular alterations, and rare exposure factors are given relatively more consideration. Non-small cell lung cancer (NSCLC) accounts for the majority of all cases and includes adenocarcinoma, squamous-cell carcinoma, and others. Adenocarcinoma can occur relatively often even in nonsmokers, while squamous-cell carcinoma is known to tend to be more strongly linked to smoking. Small cell lung cancer (SCLC) is very closely related to smoking and tends to progress rapidly.
In regions where screening is performed, "the distribution of stages at the time of detection" may differ. When screening works well, detection at early stages increases and there is room for treatment outcomes to improve, but at the same time problems such as false positives and overdiagnosis must also be considered.
Pathogenesis
Lung cancer can be understood as a process in which cells of the lung or bronchi lose normal growth control after undergoing multiple genetic damage events. Exposures such as tobacco smoke, asbestos, radon, and air pollution directly damage DNA or indirectly increase damage through inflammation and oxidative stress. A single instance of damage does not immediately produce cancer; rather, cancer cells arise as multiple changes accumulate over a long period of time.
When cells become cancerous, they acquire several "abilities." They switch on their own growth signals, ignore signals to stop, survive even in situations in which they should die, invade surrounding tissue, create blood vessels to receive nutrients, and eventually spread to other organs through the lymphatics or blood vessels (metastasis). The change that drives this process is called a "driver mutation," and targeted therapy aims at this point.
In non-small cell lung cancer (NSCLC), driver mutations vary from patient to patient, and the type of mutation has a large effect on treatment and prognosis. In contrast, in small cell lung cancer (SCLC), rather than being clearly defined by a single driver mutation, aggressive growth often results from factors such as loss of function of tumor suppressor genes.
Lung cancer also interacts with the immune environment around the tumor. Even when immune cells try to attack the cancer, cancer cells can survive by suppressing the immune response like a "brake," and immune checkpoint inhibitors (ICI) are based on the concept of releasing this brake to help the immune system attack the cancer again.
Symptoms
In the early stage, lung cancer may have no symptoms or very vague ones. This is why screening is important in high-risk groups. The most common symptom is cough. If a newly started cough persists for several weeks or more, or an existing cough suddenly worsens, evaluation is needed. Blood-tinged sputum (hemoptysis) can be a warning sign even in small amounts. Shortness of breath can appear when the tumor blocks an airway or when complications such as atelectasis, pneumonia, or pleural fluid (pleural effusion) develop. Chest pain can occur when the tumor irritates the pleura or chest wall or invades nerves.
Systemic symptoms also frequently accompany it. Loss of appetite, weight loss, fatigue, low-grade fever, and night sweats may appear. In addition, lung cancer can metastasize to the brain, bones, liver, adrenal glands, and elsewhere, so symptoms differ depending on the site of metastasis. Brain metastasis can cause neurological symptoms such as headache, nausea, dizziness, seizures, and paralysis, and bone metastasis can appear as pain or fractures.
Some lung cancers produce hormone-like substances that cause systemic symptoms. For example, vomiting, changes in consciousness, and lethargy may appear first because of elevated blood calcium (hypercalcemia) or low sodium (hyponatremia). In such cases, lung cancer may be found during evaluation of the cause even if "lung symptoms" are not obvious.
Signs
Signs are objective findings that medical staff confirm through examination and testing. On auscultation, localized decreased breath sounds, crackles, or wheezes may be heard, and imaging may show atelectasis, findings of pneumonia, pleural fluid (pleural effusion), or enlarged mediastinal lymph nodes. Palpable lymph nodes in the neck or above the collarbone are important because they can suggest metastasis.
Characteristic signs may also appear depending on the location of the tumor. A tumor at the top of the lung (lung apex) can cause shoulder pain, pain radiating to the arm, or numbness of the hand, and if it affects the sympathetic nerves, findings such as drooping of the eyelid or pupil changes may occur. Superior vena cava syndrome (SVC syndrome) may appear, in which a large tumor compresses a blood vessel, causing swelling of the face, neck, and arms and shortness of breath.
There may be findings in which the shape of the nails changes, such as clubbing, or cases accompanied by joint pain, such as hypertrophic pulmonary osteoarthropathy. Such changes can be a sign that "there is a chronic disease in the lungs or chest," so if they appear together with symptoms, evaluation of the cause is needed.
Screening
The purpose of lung cancer screening is to find lung cancer early in high-risk groups among people without symptoms and thereby reduce deaths. Currently, the most representative method is low-dose chest CT (LDCT, Low-Dose Computed Tomography). It can detect small nodules relatively well while using less radiation than regular CT, and evidence has accumulated that it can reduce lung cancer deaths in high-risk groups.
However, screening offers great benefit only in "appropriate candidates." Testing people at low risk increases false positives (cases in which suspicious findings appear even though there is no cancer), and unnecessary follow-up CT scans, invasive tests, and anxiety can increase. The problem of overdiagnosis is also discussed, in which lesions that grow very slowly and would never cause a problem in a person's lifetime are found and lead to treatment.
In actual practice, high-risk groups are usually defined by age and smoking history (pack-years and the like), and LDCT is repeated at set intervals. When a nodule is found, follow-up imaging is done according to its size, shape, and growth rate, or, if necessary, PET-CT and biopsy are performed. Screening is not "a single test" but a program that includes interpretation and follow-up, so it is best to decide on it together with medical staff.
Diagnosis
When lung cancer is suspected, evaluation usually begins with imaging tests. Chest X-rays are readily accessible but can miss small lesions, so if there is suspicion, a detailed evaluation is done with chest CT. CT is key to evaluating the location and size of the tumor, lymph node involvement, and pleural invasion. PET-CT and brain magnetic resonance imaging (MRI) may be used to evaluate metastasis.
The diagnosis is confirmed by biopsy. Lesions inside the airway are approached with bronchoscopy, and if necessary, endobronchial ultrasound (EBUS) is used to sample the mediastinal lymph nodes with a needle. For peripheral nodules, CT-guided percutaneous biopsy is sometimes performed. Depending on the patient's situation, pleural fluid cytology or surgical biopsy may be needed.
After diagnosis, the stage (how far it has spread) must be determined accurately for the treatment strategy to be decided. In addition, in non-small cell lung cancer (NSCLC), targetable mutations such as EGFR, ALK, ROS1, RET, BRAF, MET, and NTRK and immune markers such as PD-L1 are tested to determine the drug. In other words, modern lung cancer diagnosis works as a single bundle of "imaging + tissue + molecular testing + staging."
Treatment
Treatment of lung cancer depends on the stage, histologic type, molecular characteristics, and general condition. In early stages, the goal is cure. Surgery often removes the lobe of the lung containing the tumor, and the extent of resection can vary depending on the patient's condition. When surgery is difficult or not desired, high-precision radiation therapy such as stereotactic body radiation therapy (SBRT) can be an alternative.
In locally advanced non-small cell lung cancer (NSCLC), multidisciplinary treatment combining surgery, chemotherapy, and radiation therapy is common. In metastatic (stage 4) non-small cell lung cancer, targeted therapy may take priority depending on the results of molecular testing, and if there is no target, chemotherapy and immunotherapy are used together, or treatment intensity is adjusted according to the patient's condition. In small cell lung cancer (SCLC), systemic treatment is central; chemotherapy is the foundation, and radiation therapy may be used together depending on the stage and situation.
An important pillar at every stage is palliative care. This does not mean "giving up on treatment"; it is medical care that helps reduce symptoms such as pain, shortness of breath, anxiety, and fatigue and maintain quality of life. Providing it alongside treatment from the early stage of diagnosis can reduce the burden of the treatment process and help patients and families make plans.
Prognosis
The prognosis of lung cancer is determined above all by "the stage at diagnosis." In early stages in which the cancer is confined to the lung, cure can be expected with surgery or high-precision radiation therapy, but when there is lymph node metastasis or distant metastasis, cure becomes difficult and the goal of treatment often shifts to prolonging survival and controlling symptoms.
Histologic type is also a major variable. Small cell lung cancer (SCLC) grows and metastasizes rapidly, and even when it responds to treatment, the risk of recurrence is high, so the prognosis tends to be unfavorable. Non-small cell lung cancer (NSCLC) has varied prognoses depending on the stage and subtype, and when there is a targetable mutation, there are cases in which the disease can be controlled for a considerable period with appropriate targeted therapy. Immunotherapy offers the prospect of long-term response in some patients, but molecular characteristics, immune markers, general condition, and other factors must be considered together.
Patient factors also have a large effect on prognosis. Lung and heart function, comorbidities, nutritional status, and whether there has been weight loss affect the choice of treatment, side effects, and resilience. Ultimately, the prognosis of lung cancer is determined by a combination of "stage + type + molecular characteristics + patient condition + access to treatment."
Prevention
The key to preventing lung cancer is quitting smoking. Quitting smoking not only reduces the risk of developing lung cancer but also helps improve the effectiveness of treatment and reduce complications in people who have already been diagnosed with lung cancer. The success rate of quitting can increase when counseling, medication, and nicotine replacement therapy are used together.
Reducing environmental exposure is also important. Because radon concentrations can be high depending on the region and building structure, mitigation measures such as ventilation and sealing entry pathways can be considered after measurement. In occupations with exposure to asbestos or certain chemicals, workplace safety rules and wearing protective equipment are essential. On days with severe air pollution, reducing prolonged outdoor exposure and appropriately managing indoor air and ventilation can be helpful.
For high-risk groups, screening can be part of the prevention strategy. Low-dose chest CT (LDCT) can increase the opportunity for early detection in appropriate candidates, but because there are also harms such as false positives and overdiagnosis, the decision should be tailored to the individual's situation.
It is helpful to understand lung cancer prevention not as something that ends with "a single test" or "a single resolution," but as a long-term health management process that includes reducing smoking exposure, managing environmental risks, and, for high-risk groups, participating in a screening program.